Merck pulls plug on Vioxx; rivals step up promo efforts

Share this article:
In the wake of Merck's decision to withdraw Vioxx because of unfavorable clinical trials data, Pfizer and Boehringer Ingelheim/Abbot Laboratories have stepped up efforts to promote their respective rival COX-2 inhibitors, Celebrex and Mobic.
Pfizer this week placed a full-page advertisement in The New York
Times positioning Celebrex as a safe alternative to Vioxx, while
Ingelheim/Abbot booked space in the Wall Street Journal, promoting a 30-day free trial of Mobic to consumers with a prescription.
Merck had pulled the plug on Vioxx because of recently emerged
clinical trials data showing a link between the blockbuster drug and
increased risk of heart attack and stroke.
Vioxx, a key product in Merck's portfolio, is taken by 2 million people
worldwide and reached sales of approximately $2.5 billion in 2003.
While its removal from the market could give a healthy boost to competitors like Celebrex and Bextra (also manufactured by Pfizer), question marks surround the risks of the category as a whole, and all COX-2 drugs will come under increased scrutiny by the FDA.
The withdrawal of Vioxx tops off years of questions over the safety of the drug. "We have been concerned and aware for quite a few years about the risk," Dr. Steven Galson, acting director of the FDA's Center for Drug Evaluation and Research, said during an FDA conference call with reporters. "This is not a surprise."
Prior to Merck's decision to pull the product from pharmacy shelves,
Pfizer had been planning for a new advertising campaign to break this fall.That account is being handled by Publicis Groupe's Kaplan Thaler. Professional advertising for Vioxx was handled by FCB Healthcare, with DDB Worldwide holding the consumer account.
The withdrawal of Vioxx may also have an impact on Merck pipeline
drug Arcoxia, an anti-inflammatory that was to be Vioxx's successor.The FDA is expected to make a decision
on Arcoxia by Oct. 30.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...